Daiichi Sankyo: Europe poses huge challenge for pharma
June 9, 2011Research and Development, Sales and Marketing Cancer, Daiichi Sankyo, pricing
Japanese pharma company Daiichi Sankyo is expanding its European operations, creating a new oncology business unit. But outlining its plans …
NICE thumbs up for Allergan’s Ozurdex
June 9, 2011Sales and Marketing Allergan, BRVO, CVRO, NICE, Ozurdex
In draft guidance NICE has recommended the use of Allergan’s eye treatment Ozurdex.NICE’s final decision on Ozurdex (dexamethasone) is expected …
Merck Serono signs neurodegenerative collaboration
June 9, 2011Research and Development Affectis Pharmaceuticals, Merck Serono
Merck Serono has struck a deal with biotech firm Affectis Pharmaceuticals to develop oral neurodegeneration compounds. The companies will commercialise …
The Pharmafocus Interview: Richard Barker
June 9, 2011Research and Development, Sales and Marketing ABPI, Dr Richard Barker, vita
Dr Richard Barker has been at the helm of the UK pharma industry for over six years, but is now …
Price transparency and timing at risk, warns EFPIA
June 9, 2011Sales and Marketing Drug pricing, EFPIA, medicines pricing, pricing
Europe’s pharmaceutical industry has warned that a review of EU law could undermine the pricing and reimbursement of medicines. The …
Free webinar on An Introduction to Scientific Advice in the EU
June 8, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Following the success of the recent pharmacovigilance webinars delivered, Wainwright Associates are offering a webinar on An Introduction to Scientific …
Red Kite to merge with MSI
June 8, 2011Sales and Marketing Cello, MSI, Red Kite, pharmaceutical marketing
Strategic marketing group Cello has expanded its healthcare portfolio with the acquisition of consultancy firm Red Kite. The move has …
UK prime minister to rein in health reforms
June 8, 2011Health and Social Care Bill, NHS reforms
The UK prime minister David Cameron has put forward five major changes to the government’s beleaguered Health and Social Care …
Oxford BioMedica appoints Alex Lewis to strategy role
June 8, 2011Research and Development appointment, research and development
Oxford, UK-based gene therapy company Oxford BioMedica has appointed Dr Alex Lewis as director of corporate activities and strategy, and …
Digital Pharma: Pfizer’s mobile-powered ‘virtual’ clinical trial
June 8, 2011Research and Development Digital Pharma blog, Pfizer, clinical trials
In an industry first Pfizer is to use mobile phone and web-based technology to collect study data for pharma’s first …
Roche and Merck collaborate on personalised cancer tests
June 8, 2011Research and Development Merck, Roche, personalised medicine
Roche has signed a deal to develop diagnostic tests for products in Merck’s oncology pipeline, in a bid to make …
Promoting UK biotech’s voice and mission
June 8, 2011Research and Development ERBI, One Nucleus, biotech
One Nucleus is a new organisation formed from the merger of two of England’s regional networks – ERBI (Eastern Region …
UK suing Servier over alleged generic blocking
June 7, 2011Sales and Marketing Peridopril, Servier, generics
The UK government is taking Servier to court for allegedly blocking generic versions of its blood pressure drug Perindopril from …
Bayer submits Lucentis rival for European approval
June 7, 2011Sales and Marketing Bayer, Lucentis, Regeneron, VEGF Trap-Eye
Bayer Healthcare has submitted its new eye drug to European regulators for approval to treat age-related macular degeneration (wet AMD). …
Merck plans cancer drug submissions later this year
June 7, 2011Research and Development, Sales and Marketing Merck & Co, ridaforolimus
Merck & Co is to submit its oral investigational cancer drug ridaforolimus to European and US regulators later this year …
European falsified meds directive: implications for manufacturers
June 7, 2011Manufacturing and Production APIs, GDP, GMP, excipients, pharma manufacturing
The Council of the European Union gave its backing to the new Directive on Falsified Medicines on May 27, setting …
Erbitux meets gold standard in rectal cancer
June 7, 2011Research and Development, Sales and Marketing Erbitux, Merck Serono, rectal cancer
Studies of Merck Serono’s Erbitux in rectal cancer have shown improved overall survival, a gold standard measure in oncology trials. …
New head of finance at Bayer
June 7, 2011Sales and Marketing appointment, sales and marketing
Bayer has appointed Peter Müller as its new head of finance. Currently head of the corporate finance unit within the …
Almirall appoints Daniel MartÃnez Carretero as finance head
June 6, 2011Sales and Marketing appointment, sales and marketing
Spanish pharma company Almirall has appointed Daniel MartÃnez Carretero as its chief financial officer. In addition to Finance, Daniel will …
Roche impresses at ASCO with vemurafenib
June 6, 2011Research and Development, Sales and Marketing ASCO, Roche, skin cancer, vemurafenib
Roche’s vemurafenib has proven one of the stars of the ASCO cancer conference by increasing overall survival in skin cancer …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
